Optimal pharmacological management of HCM by clinical manifestations
Pablo Garcia-Pavia, MD, PhD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
James Januzzi, MD
Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy
Marianna Fontana, MD
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Javed Butler, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.